DE19646372C1 - Genotyp und Phänotyp koppelnde Verbindung - Google Patents
Genotyp und Phänotyp koppelnde VerbindungInfo
- Publication number
- DE19646372C1 DE19646372C1 DE1996146372 DE19646372A DE19646372C1 DE 19646372 C1 DE19646372 C1 DE 19646372C1 DE 1996146372 DE1996146372 DE 1996146372 DE 19646372 A DE19646372 A DE 19646372A DE 19646372 C1 DE19646372 C1 DE 19646372C1
- Authority
- DE
- Germany
- Prior art keywords
- structural unit
- terminator
- codon
- mrna
- structural
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Peptides Or Proteins (AREA)
Description
- 1. Die ortsspezifische Kopplung kann erfindungsgemäß unter Verwendung eines Sinn-Codons als Terminatorcodon erfolgen, welches nicht stromaufwärts im codierenden Bereich der Struktur einheit A bereits vorhanden ist. Vorzugsweise wird hierfür das seltene AGA-Codon herangezogen, wobei in diesem Fall der Trans lationsansatz keine für das AGA-Codon spezifische tRNA enthalten sollte. Am AGA-Codon findet erfindungsgemäß der Peptidyltransfer auf den Terminator statt, welcher in diesem Fall nicht mit den entsprechenden tRNA-Molekülen des Translationsgemisches um die Besetzung der Aminoacyl-Bindungsstelle des Ribosoms konkurriert.
- 2. Die ortsspezifische Kopplung kann erfindungsgemäß auch durch eine Codon-Anticodon-Wechselwirkung erfolgen. Es ist erfindungsgemäß möglich, den Terminator über einen Spacer mit anderen Bereichen der Struktureinheit A zu verknüpfen. Im Falle der ortsspezifischen Kopplung mittels Codon-Anticodon-Wechsel wirkung wird ein Spacer mit tRNA-Struktur gewählt, welcher am Terminatorcodon den Transfer der naszierenden Struktureinheit B auf den Terminator vermittelt. Vorzugsweise wird auch hierfür wie oben beschrieben das AGA-Codon herangezogen, so daß das Translationsgemisch entsprechend vorbehandelt werden sollte.
Vorbereitende Schritte: (Endprodukt einsetzbar für beliebige Kopplungsreaktionen)
- 1. Chemische Aminoacylierung des Diribonukleotids pC₇₅pA₇₆ mit einer Aminosäure, deren Seitenkette R mit einem beliebigen Diribonukleotid oder Didesoxyribonukleotid modifiziert ist [R = -CH₂-3′-pXpXp-5′];
- 2. Ligation des aminoacylierten Diribonukleotids mit einer für das Codon AGA spezifischen tRNA (C₇₄-Ende!) durch T4 -RNA-Ligase;
- 3. Reinigung der korrekten und funktionalen Ligationsprodukte (Aminoacyl-tRNAs) durch immobilisierten Elongationsfaktor EF-TU in Gegenwart von GTP;
- 4. Diversifizierung des entsprechenden Polypeptid-Strukturgens durch chemische Resynthese (codon-based mutagenesis) oder durch Mutagenese- und/oder Rekombinations-PCR Unter dem Begriff "codon-based mutagenesis" wird im Sinne der Erfindung eine chemische Synthese von DNA verstanden, bei der statt Monomer-Bausteinen Trimere eingesetzt werden, die jeweils für eine bestimmte Aminosäure codieren. Durch Mischen von TrimerBausteinen bei der Synthese kann der Einbau verschiedener Codons im gewünschten Verhältnis an jeder Position erzielt werden.
- Unter dem Begriff "Mutagenese-PCR" wird im Sinne der Erfindung eine in-vitro-Amplifikation von DNA verstanden, bei der durch bestimmte Bedingungen eine fehlerhafte Verdopplung der DNA erzwungen wird.
- Unter dem Begriff "Rekombinations-PCR" wird im Sinne der Erfindung eine in-vitro-Amplifikation von DNA verstanden, bei der durch Mischen von zufälligen DNA-Subfragmenten homologer Gene neue, mosaikartige Gene synthetisiert werden. Dieser Prozeß ist mit einer natürlichen Rekom bination vergleichbar;
- 5. Erneute Amplifikation (Reamplification) der synthetisierten Strukturgene durch PCR, wobei der 5′-Primer einen Promotor (z. B. T7-Promotor) und eine Translationsinitationsregion (einschließlich ATG-Start- Codon), während der 3′-Primer sechs Histidin-Codons, das Terminatorcodon AGA und das Nonsense-Codon TAG einführt;
- 6. Präparation einer Spacer-DNA (z. B. chemische Synthese oder durch PCR), deren 5′-terminale Sequenz mit der 3′-termina len Sequenz des reamplifizierten Strukturgens überlappt;
- 7. Verspleißen beider DNA-Fragmente durch SOE-PCR (splicing by overlap extension), wobei der Spacer den 3′ -terminalen Fusionspartner bildet.
- Unter dem Begriff "SOE-PCR" wird im Sinne der Erfindung eine in-vitro-Amplifikation von DNA verstanden, bei der aufgrund überlappender Bereiche zwei DNA-Fragmente mit einander verspleißt werden;
- 8. In-vitro-Transkription des Fusionsgens mit m⁷GpppG (5′- Cap-Struktur) als Primer (z. B. mit T7-DNA-Polymerase);
- 9. Reinigung des run-off-Transkriptes durch Polyacrylamidgel elektrophorese;
- 10. Ligation der synthetisierten RNA (freies 3′-OH-Ende; 5′-Ende durch Cap-Struktur geschützt) mit der Aminosäure- Seitenkette der aminoacylierten tRNA durch T4-RNA-Ligase;
- 11. Reinigung des Produktes durch Polyacrylamidgelelektro phorese;
- 12. In-vitro-Translation der mRNA und Kopplung der naszierenden Polypeptidkette durch die für das AGA-Codon spezifische, aminoacylierte tRNA in Gegenwart eines E. coli Trans lationsgemisches, das durch entsprechende Vorbehandlung keine für das Arginin-Codon AGA spezifische tRNA-Moleküle mehr enthält;
- 13. Abtrennung der Translationsfaktoren und Reinigung der Fusionsmoleküle durch Affinitätschromatographie an einer Nickel -NTA-Matrix.
- Unter dem Begriff "Nickel-NTA-Matrix" wird im Sinne der Erfindung eine Matrix verstanden, die aufgrund eines immobilisierten Nickelions die Reinigung von Oligohistidin haltigen Biomolekülen ermöglicht;
- 14. In-vitro-Selektion von Fusionsmolekülen mit gewünschten Eigenschaften (z. B. durch Panning);
- 15. Reverse Transkription der angereicherten Fusionsmoleküle und Reamplifikation der genetischen Information durch PCR, wobei der 5′-Primer wiederum den Promoter und die Trans lationsinitiationsregion einführt, während der 3′-Primer mit der 3′-terminalen Sequenz des Spacers hybridisiert;
- 16. Wiederholung des beschriebenen Verfahrens ab Schritt 8.
Claims (13)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95117787 | 1995-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE19646372C1 true DE19646372C1 (de) | 1997-06-19 |
Family
ID=8219806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE1996146372 Expired - Lifetime DE19646372C1 (de) | 1995-11-11 | 1996-11-09 | Genotyp und Phänotyp koppelnde Verbindung |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE19646372C1 (de) |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998037186A1 (en) * | 1997-02-18 | 1998-08-27 | Actinova Limited | In vitro peptide or protein expression library |
WO1999002671A1 (en) * | 1997-07-07 | 1999-01-21 | Medical Research Council | In vitro sorting method |
WO1999011785A1 (en) * | 1997-09-02 | 1999-03-11 | Rowett Research Services Limited | Chimeric binding peptide library screening method |
WO1999011777A1 (en) * | 1997-09-03 | 1999-03-11 | Biovation Limited | Methods for protein screening |
EP0962527A1 (de) * | 1996-10-17 | 1999-12-08 | Mitsubishi Chemical Corporation | Molekül, welches Genotyp und Phänotyp zusammenführt und dessen Anwendungen |
GB2338237A (en) * | 1997-02-18 | 1999-12-15 | Actinova Ltd | In vitro peptide or protein expression library |
EP1196637A1 (de) * | 1999-07-27 | 2002-04-17 | Phylos, Inc. | Peptidakzeptor ligationsverfahren |
WO2002081685A1 (de) * | 2001-04-03 | 2002-10-17 | Phylos Inc. | PEPTIDAKZEPTOR/tRNA-HYBRIDMOLEKÜL UND SEINE VERWENDUNG ZUR HERSTELLUNG VON CODON-SPEZIFISCH ARRETIERTEN TRANSLATIONSKOMPLEXEN |
US6489116B2 (en) | 2000-01-24 | 2002-12-03 | Phylos, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
EP0971946A4 (de) * | 1997-01-21 | 2002-12-04 | Gen Hospital Corp | Selektion von proteinen mittels rns-protein fusionen |
WO2002103008A2 (en) * | 2001-06-20 | 2002-12-27 | Nuevolution A/S | Templated molecules and methods for using such molecules |
WO2004013070A2 (en) | 2002-08-01 | 2004-02-12 | Nuevolution A/S | Multi-step synthesis of templated molecules |
WO2004083427A2 (en) * | 2003-03-20 | 2004-09-30 | Nuevolution A/S | Ligational encoding of small molecules |
WO2004110964A2 (en) * | 2003-06-16 | 2004-12-23 | Nuevolution A/S | Encoded molecules by translation (emt) |
EP1522581A2 (de) * | 1999-01-07 | 2005-04-13 | Medical Research Council | Optische Sortiermethode |
EP1540013A2 (de) * | 2002-08-19 | 2005-06-15 | President And Fellows Of Harvard College | Entwicklung einer neuen molekularen funktion |
US7070928B2 (en) | 2001-03-19 | 2006-07-04 | President And Fellows Of Harvard College | Evolving new molecular function |
WO2006135654A2 (en) * | 2005-06-07 | 2006-12-21 | President And Fellows Of Harvard College | Polymer evolution via templated synthesis related applications |
US7195880B2 (en) | 1998-12-02 | 2007-03-27 | Adnexus Therapeutics, Inc. | DNA-protein fusions and uses thereof |
US7270950B2 (en) | 1997-01-21 | 2007-09-18 | The General Hospital Corporation | Nucleic acid-protein fusions and methods of making and selecting fusions |
US7429467B2 (en) | 2001-11-16 | 2008-09-30 | Medical Research Council | Emulsion compositions |
EP2045321A2 (de) | 2005-05-27 | 2009-04-08 | Direvo Biotech AG | Serinproteasen mit veränderter Empfindlichkeit gegen aktivitätsmodulierende Substanzen |
US7727713B2 (en) | 2001-06-20 | 2010-06-01 | Nuevolution A/S | Templated molecules and methods for using such molecules |
US7842457B2 (en) | 2003-01-29 | 2010-11-30 | 454 Life Sciences Corporation | Bead emulsion nucleic acid amplification |
US8017323B2 (en) | 2003-03-26 | 2011-09-13 | President And Fellows Of Harvard College | Free reactant use in nucleic acid-templated synthesis |
US8048627B2 (en) | 2003-07-05 | 2011-11-01 | The Johns Hopkins University | Method and compositions for detection and enumeration of genetic variations |
US8206901B2 (en) | 2002-10-30 | 2012-06-26 | Nuevolution A/S | Method for the synthesis of a bifunctional complex |
US8207093B2 (en) | 1997-01-21 | 2012-06-26 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
US8278427B2 (en) | 2000-12-14 | 2012-10-02 | Keio University | Molecule for assigning genotype to phenotype and components thereof as well as method for constructing assigning molecule and method for utilizing assigning molecule |
US8728483B2 (en) | 2008-05-22 | 2014-05-20 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
US8791053B2 (en) | 2002-09-27 | 2014-07-29 | Mpm-Holding Aps | Spatially encoded polymer matrix |
US8808984B2 (en) | 2002-03-15 | 2014-08-19 | Neuvolution A/S | Method for synthesising templated molecules |
US8969289B2 (en) | 2010-05-03 | 2015-03-03 | Bristol-Myers Squibb Company | Serum albumin binding molecules |
US9017655B2 (en) | 2008-11-24 | 2015-04-28 | Bristol-Myers Squibb Company | Bispecific EGFR/IGFIR binding molecules |
US9017623B2 (en) | 2007-02-06 | 2015-04-28 | Raindance Technologies, Inc. | Manipulation of fluids and reactions in microfluidic systems |
US9096951B2 (en) | 2003-02-21 | 2015-08-04 | Nuevolution A/S | Method for producing second-generation library |
US9121110B2 (en) | 2002-12-19 | 2015-09-01 | Nuevolution A/S | Quasirandom structure and function guided synthesis methods |
US9234028B2 (en) | 2008-02-14 | 2016-01-12 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
US9359601B2 (en) | 2009-02-13 | 2016-06-07 | X-Chem, Inc. | Methods of creating and screening DNA-encoded libraries |
US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
US9574189B2 (en) | 2005-12-01 | 2017-02-21 | Nuevolution A/S | Enzymatic encoding methods for efficient synthesis of large libraries |
US10221232B2 (en) | 2006-11-22 | 2019-03-05 | Bristol-Myers Squibb Company | Methods of treating cancer by administering IGF-IR binding molecules |
US10442851B2 (en) | 2014-03-20 | 2019-10-15 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type III domains |
US10766946B2 (en) | 2015-09-23 | 2020-09-08 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type III domains |
US10865409B2 (en) | 2011-09-07 | 2020-12-15 | X-Chem, Inc. | Methods for tagging DNA-encoded libraries |
US11118215B2 (en) | 2003-09-18 | 2021-09-14 | Nuevolution A/S | Method for obtaining structural information concerning an encoded molecule and method for selecting compounds |
US11225655B2 (en) | 2010-04-16 | 2022-01-18 | Nuevolution A/S | Bi-functional complexes and methods for making and using such complexes |
US11674135B2 (en) | 2012-07-13 | 2023-06-13 | X-Chem, Inc. | DNA-encoded libraries having encoding oligonucleotide linkages not readable by polymerases |
-
1996
- 1996-11-09 DE DE1996146372 patent/DE19646372C1/de not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
Recherche in CA, BIOSIS, WPIDS * |
Cited By (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1477561A3 (de) * | 1996-10-17 | 2006-04-12 | Mitsubishi Chemical Corporation | Molekül, welches Genotyp und Phänotyp zusammenführt und dessen Anwendungen |
EP0962527A1 (de) * | 1996-10-17 | 1999-12-08 | Mitsubishi Chemical Corporation | Molekül, welches Genotyp und Phänotyp zusammenführt und dessen Anwendungen |
EP0962527A4 (de) * | 1996-10-17 | 2000-05-31 | Mitsubishi Chem Corp | Molekül, welches genotyp und phänotyp zusammenführt und dessen anwendungen |
EP1477561A2 (de) * | 1996-10-17 | 2004-11-17 | Mitsubishi Chemical Corporation | Molekül, welches Genotyp und Phänotyp zusammenführt und dessen Anwendungen |
EP0971946A4 (de) * | 1997-01-21 | 2002-12-04 | Gen Hospital Corp | Selektion von proteinen mittels rns-protein fusionen |
US7270950B2 (en) | 1997-01-21 | 2007-09-18 | The General Hospital Corporation | Nucleic acid-protein fusions and methods of making and selecting fusions |
EP1712623A3 (de) * | 1997-01-21 | 2008-10-15 | The General Hospital Corporation | Selektion von Proteinen unter Verwendung von RNA-protein-fusionen |
US8207093B2 (en) | 1997-01-21 | 2012-06-26 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
GB2338237A (en) * | 1997-02-18 | 1999-12-15 | Actinova Ltd | In vitro peptide or protein expression library |
WO1998037186A1 (en) * | 1997-02-18 | 1998-08-27 | Actinova Limited | In vitro peptide or protein expression library |
GB2338237B (en) * | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
US7582446B2 (en) | 1997-07-07 | 2009-09-01 | Medical Research Council | In vitro sorting method |
US7138233B2 (en) | 1997-07-07 | 2006-11-21 | Medical Research Council | IN vitro sorting method |
GB2342094B (en) * | 1997-07-07 | 2002-10-23 | Medical Res Council | In vitro sorting method |
US9528106B2 (en) | 1997-07-07 | 2016-12-27 | Medical Research Council | In vitro sorting method |
WO1999002671A1 (en) * | 1997-07-07 | 1999-01-21 | Medical Research Council | In vitro sorting method |
EP1496120A3 (de) * | 1997-07-07 | 2005-05-11 | Medical Research Council | Ein in vitro Sortierverfahren |
US8367326B2 (en) | 1997-07-07 | 2013-02-05 | Medical Research Council | In vitro sorting method |
US7252943B2 (en) | 1997-07-07 | 2007-08-07 | Medical Research Council | In Vitro sorting method |
EP1801214A2 (de) | 1997-07-07 | 2007-06-27 | Medical Research Council | In-vitro-Sortierverfahren |
EP1801214A3 (de) * | 1997-07-07 | 2009-05-20 | Medical Research Council | In-vitro-Sortierverfahren |
GB2342094A (en) * | 1997-07-07 | 2000-04-05 | Medical Res Council | In vitro sorting method |
EP1496120A2 (de) * | 1997-07-07 | 2005-01-12 | Medical Research Council | Ein in vitro Sortierverfahren |
US7638276B2 (en) | 1997-07-07 | 2009-12-29 | 454 Life Sciences Corporation | In vitro sorting method |
WO1999011785A1 (en) * | 1997-09-02 | 1999-03-11 | Rowett Research Services Limited | Chimeric binding peptide library screening method |
US8735146B2 (en) | 1997-09-02 | 2014-05-27 | The University Court Of The University Of Aberdeen | Chimeric binding peptide library screening method |
WO1999011777A1 (en) * | 1997-09-03 | 1999-03-11 | Biovation Limited | Methods for protein screening |
US7195880B2 (en) | 1998-12-02 | 2007-03-27 | Adnexus Therapeutics, Inc. | DNA-protein fusions and uses thereof |
EP1522581A3 (de) * | 1999-01-07 | 2005-05-04 | Medical Research Council | Optische Sortiermethode |
EP1522581A2 (de) * | 1999-01-07 | 2005-04-13 | Medical Research Council | Optische Sortiermethode |
EP1870417A3 (de) * | 1999-07-27 | 2008-06-11 | Adnexus Therapeutics, Inc. | Peptidakzeptorbindungsverfahren |
US7078197B2 (en) | 1999-07-27 | 2006-07-18 | Compound Therapeutics, Inc. | Peptide acceptor ligation methods |
US7790421B2 (en) | 1999-07-27 | 2010-09-07 | Bristol-Myers Squibb Company | Peptide acceptor ligation methods |
EP1196637A4 (de) * | 1999-07-27 | 2003-11-12 | Phylos Inc | Peptidakzeptor ligationsverfahren |
EP1196637A1 (de) * | 1999-07-27 | 2002-04-17 | Phylos, Inc. | Peptidakzeptor ligationsverfahren |
US6489116B2 (en) | 2000-01-24 | 2002-12-03 | Phylos, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
US8278427B2 (en) | 2000-12-14 | 2012-10-02 | Keio University | Molecule for assigning genotype to phenotype and components thereof as well as method for constructing assigning molecule and method for utilizing assigning molecule |
US7998904B2 (en) | 2001-03-19 | 2011-08-16 | President And Fellows Of Harvard College | Evolving new molecular function |
US7223545B2 (en) | 2001-03-19 | 2007-05-29 | President And Fellows Of Harvard College | Evolving new molecular function |
US7557068B2 (en) | 2001-03-19 | 2009-07-07 | President And Fellows Of Harvard College | Evolving new molecular function |
US7442160B2 (en) | 2001-03-19 | 2008-10-28 | President And Fellows Of Harvard College | Evolving new molecular function |
US7070928B2 (en) | 2001-03-19 | 2006-07-04 | President And Fellows Of Harvard College | Evolving new molecular function |
WO2002081685A1 (de) * | 2001-04-03 | 2002-10-17 | Phylos Inc. | PEPTIDAKZEPTOR/tRNA-HYBRIDMOLEKÜL UND SEINE VERWENDUNG ZUR HERSTELLUNG VON CODON-SPEZIFISCH ARRETIERTEN TRANSLATIONSKOMPLEXEN |
EP2305808A1 (de) * | 2001-06-20 | 2011-04-06 | Nuevolution A/S | Matrizenabhängige Moleküle und Verfahren zur Verwendung derartiger Moleküle |
EP1905829A2 (de) * | 2001-06-20 | 2008-04-02 | Nuevolution A/S | Templierte Moleküle und Verfahren zur Verwendung derartiger Moleküle |
WO2002103008A2 (en) * | 2001-06-20 | 2002-12-27 | Nuevolution A/S | Templated molecules and methods for using such molecules |
US10669538B2 (en) | 2001-06-20 | 2020-06-02 | Nuevolution A/S | Templated molecules and methods for using such molecules |
EP1905829A3 (de) * | 2001-06-20 | 2009-06-24 | Nuevolution A/S | Templierte Moleküle und Verfahren zur Verwendung derartiger Moleküle |
US8932992B2 (en) | 2001-06-20 | 2015-01-13 | Nuevolution A/S | Templated molecules and methods for using such molecules |
WO2002103008A3 (en) * | 2001-06-20 | 2003-11-27 | Nuevolution As | Templated molecules and methods for using such molecules |
US7727713B2 (en) | 2001-06-20 | 2010-06-01 | Nuevolution A/S | Templated molecules and methods for using such molecules |
US8153364B2 (en) | 2001-11-16 | 2012-04-10 | Mrc | Emulsion compositions |
US7429467B2 (en) | 2001-11-16 | 2008-09-30 | Medical Research Council | Emulsion compositions |
US8153402B2 (en) | 2001-11-16 | 2012-04-10 | Medical Research Council | Emulsion compositions |
US10731151B2 (en) | 2002-03-15 | 2020-08-04 | Nuevolution A/S | Method for synthesising templated molecules |
US8808984B2 (en) | 2002-03-15 | 2014-08-19 | Neuvolution A/S | Method for synthesising templated molecules |
WO2004013070A2 (en) | 2002-08-01 | 2004-02-12 | Nuevolution A/S | Multi-step synthesis of templated molecules |
US10730906B2 (en) | 2002-08-01 | 2020-08-04 | Nuevolutions A/S | Multi-step synthesis of templated molecules |
WO2004013070A3 (en) * | 2002-08-01 | 2004-03-25 | Nuevolution As | Multi-step synthesis of templated molecules |
US7491494B2 (en) | 2002-08-19 | 2009-02-17 | President And Fellows Of Harvard College | Evolving new molecular function |
US8206914B2 (en) | 2002-08-19 | 2012-06-26 | President And Fellows Of Harvard College | Evolving new molecular function |
US7771935B2 (en) | 2002-08-19 | 2010-08-10 | President And Fellows Of Harvard College | Evolving new molecular function |
AU2010202702B2 (en) * | 2002-08-19 | 2012-12-06 | The President And Fellows Of Harvard College | Evolving new molecular function |
EP1540013A2 (de) * | 2002-08-19 | 2005-06-15 | President And Fellows Of Harvard College | Entwicklung einer neuen molekularen funktion |
EP1540013A4 (de) * | 2002-08-19 | 2006-06-28 | Harvard College | Entwicklung einer neuen molekularen funktion |
US8791053B2 (en) | 2002-09-27 | 2014-07-29 | Mpm-Holding Aps | Spatially encoded polymer matrix |
US8206901B2 (en) | 2002-10-30 | 2012-06-26 | Nuevolution A/S | Method for the synthesis of a bifunctional complex |
US9284600B2 (en) | 2002-10-30 | 2016-03-15 | Neuvolution A/S | Method for the synthesis of a bifunctional complex |
US9109248B2 (en) | 2002-10-30 | 2015-08-18 | Nuevolution A/S | Method for the synthesis of a bifunctional complex |
US11001835B2 (en) | 2002-10-30 | 2021-05-11 | Nuevolution A/S | Method for the synthesis of a bifunctional complex |
US10077440B2 (en) | 2002-10-30 | 2018-09-18 | Nuevolution A/S | Method for the synthesis of a bifunctional complex |
US8722583B2 (en) | 2002-10-30 | 2014-05-13 | Nuevolution A/S | Method for selecting a chemical entity from a tagged library |
US9121110B2 (en) | 2002-12-19 | 2015-09-01 | Nuevolution A/S | Quasirandom structure and function guided synthesis methods |
US10240192B2 (en) | 2003-01-29 | 2019-03-26 | 454 Life Sciences Corporation | Bead emulsion nucleic acid amplification |
US8765380B2 (en) | 2003-01-29 | 2014-07-01 | 454 Life Sciences Corporation | Bead emulsion nucleic acid amplification |
US10982274B2 (en) | 2003-01-29 | 2021-04-20 | Roche Molecular Systems, Inc. | Bead emulsion nucleic acid amplification |
US7842457B2 (en) | 2003-01-29 | 2010-11-30 | 454 Life Sciences Corporation | Bead emulsion nucleic acid amplification |
US8012690B2 (en) | 2003-01-29 | 2011-09-06 | 454 Life Sciences Corporation | Bead emulsion nucleic acid amplification |
US9096951B2 (en) | 2003-02-21 | 2015-08-04 | Nuevolution A/S | Method for producing second-generation library |
WO2004083427A2 (en) * | 2003-03-20 | 2004-09-30 | Nuevolution A/S | Ligational encoding of small molecules |
EP2236606A3 (de) * | 2003-03-20 | 2010-10-20 | Nuevolution A/S | Ligationsvermittelnde Codierung von kleinen Molekülen |
WO2004083427A3 (en) * | 2003-03-20 | 2005-02-17 | Nuevolution As | Ligational encoding of small molecules |
US7915201B2 (en) | 2003-03-20 | 2011-03-29 | Nuevolution A/S | Ligational encoding of small molecules |
US8017323B2 (en) | 2003-03-26 | 2011-09-13 | President And Fellows Of Harvard College | Free reactant use in nucleic acid-templated synthesis |
WO2004110964A2 (en) * | 2003-06-16 | 2004-12-23 | Nuevolution A/S | Encoded molecules by translation (emt) |
WO2004110964A3 (en) * | 2003-06-16 | 2005-03-31 | Nuevolution As | Encoded molecules by translation (emt) |
US8048627B2 (en) | 2003-07-05 | 2011-11-01 | The Johns Hopkins University | Method and compositions for detection and enumeration of genetic variations |
US9328343B2 (en) | 2003-07-05 | 2016-05-03 | The Johns Hopkins University | Method and compositions for detection and enumeration of genetic variations |
US10604797B2 (en) | 2003-07-05 | 2020-03-31 | The Johns Hopkins University | Method and compositions for detection and enumeration of genetic variations |
US11965209B2 (en) | 2003-09-18 | 2024-04-23 | Nuevolution A/S | Method for obtaining structural information concerning an encoded molecule and method for selecting compounds |
US11118215B2 (en) | 2003-09-18 | 2021-09-14 | Nuevolution A/S | Method for obtaining structural information concerning an encoded molecule and method for selecting compounds |
EP2045321A2 (de) | 2005-05-27 | 2009-04-08 | Direvo Biotech AG | Serinproteasen mit veränderter Empfindlichkeit gegen aktivitätsmodulierende Substanzen |
WO2006135654A2 (en) * | 2005-06-07 | 2006-12-21 | President And Fellows Of Harvard College | Polymer evolution via templated synthesis related applications |
WO2006135654A3 (en) * | 2005-06-07 | 2007-04-05 | Harvard College | Polymer evolution via templated synthesis related applications |
US11702652B2 (en) | 2005-12-01 | 2023-07-18 | Nuevolution A/S | Enzymatic encoding methods for efficient synthesis of large libraries |
US9574189B2 (en) | 2005-12-01 | 2017-02-21 | Nuevolution A/S | Enzymatic encoding methods for efficient synthesis of large libraries |
US11149077B2 (en) | 2006-11-22 | 2021-10-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
US10221232B2 (en) | 2006-11-22 | 2019-03-05 | Bristol-Myers Squibb Company | Methods of treating cancer by administering IGF-IR binding molecules |
US9017623B2 (en) | 2007-02-06 | 2015-04-28 | Raindance Technologies, Inc. | Manipulation of fluids and reactions in microfluidic systems |
US9234028B2 (en) | 2008-02-14 | 2016-01-12 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
US9920108B2 (en) | 2008-02-14 | 2018-03-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
US10781247B2 (en) | 2008-02-14 | 2020-09-22 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
US10774130B2 (en) | 2008-05-22 | 2020-09-15 | Bristol-Myers Squibb Company | Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins |
US9902762B2 (en) | 2008-05-22 | 2018-02-27 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
US8728483B2 (en) | 2008-05-22 | 2014-05-20 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
US10954286B2 (en) | 2008-11-24 | 2021-03-23 | Bristol-Myers Squibb Company | Bispecific EGFR/IGFIR binding molecules |
US9771411B2 (en) | 2008-11-24 | 2017-09-26 | Bristol-Myers Squibb Company | Method of treating cancer by administering EGFR and EGFR/IGFIR binding molecules |
US10183987B2 (en) | 2008-11-24 | 2019-01-22 | Bristol-Myers Squibb Company | Polynucleotides encoding bispecific EGFR/IGF-IR binding molecules |
US9017655B2 (en) | 2008-11-24 | 2015-04-28 | Bristol-Myers Squibb Company | Bispecific EGFR/IGFIR binding molecules |
US11168321B2 (en) | 2009-02-13 | 2021-11-09 | X-Chem, Inc. | Methods of creating and screening DNA-encoded libraries |
US9359601B2 (en) | 2009-02-13 | 2016-06-07 | X-Chem, Inc. | Methods of creating and screening DNA-encoded libraries |
US11225655B2 (en) | 2010-04-16 | 2022-01-18 | Nuevolution A/S | Bi-functional complexes and methods for making and using such complexes |
US10221438B2 (en) | 2010-05-03 | 2019-03-05 | Bristol-Myers Squibb Company | Serum albumin binding molecules |
US8969289B2 (en) | 2010-05-03 | 2015-03-03 | Bristol-Myers Squibb Company | Serum albumin binding molecules |
US10934572B2 (en) | 2010-05-03 | 2021-03-02 | Bristol-Myers Squibb Company | Serum albumin binding molecules |
US9540424B2 (en) | 2010-05-03 | 2017-01-10 | Bristol-Myers Squibb Company | Serum albumin binding molecules |
US11161893B2 (en) | 2010-05-26 | 2021-11-02 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
US10273286B2 (en) | 2010-05-26 | 2019-04-30 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
US10865409B2 (en) | 2011-09-07 | 2020-12-15 | X-Chem, Inc. | Methods for tagging DNA-encoded libraries |
US11674135B2 (en) | 2012-07-13 | 2023-06-13 | X-Chem, Inc. | DNA-encoded libraries having encoding oligonucleotide linkages not readable by polymerases |
US11203630B2 (en) | 2014-03-20 | 2021-12-21 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type III domains |
US10442851B2 (en) | 2014-03-20 | 2019-10-15 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type III domains |
US10766946B2 (en) | 2015-09-23 | 2020-09-08 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type III domains |
US11434275B2 (en) | 2015-09-23 | 2022-09-06 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type III domains |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE19646372C1 (de) | Genotyp und Phänotyp koppelnde Verbindung | |
DE60034566T2 (de) | Peptidakzeptor ligationsverfahren | |
DE60038572T2 (de) | Verwendung einer vielzahl von rekombinationsstellen mit einzigartiger spezifität beim rekombinatorischen klonen | |
DE69830497T2 (de) | Bibliothek für die in-vitro Expression von Peptiden oder Proteinen | |
DE102004049479A1 (de) | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie | |
DE3050725C2 (de) | ||
DE60124678T2 (de) | Proteingerüste für antikörper-mimetika und andere bindungsproteine | |
DE69835143T2 (de) | Selektion von proteinen mittels rns-protein fusionen | |
MX2011008563A (es) | Metodos de crear y analizar/seleccionar bibliotecas codificadas por adn. | |
EP2065465A3 (de) | Prozess, Konstrukt und Konjugat zur Herstellung mehrerer Nukleinsäurekopien | |
Hoffmüller et al. | In vitro evolution and selection of proteins: ribosome display for larger libraries | |
EP2057176A2 (de) | Programmierbare oligonukleotidsynthese | |
DE2709094A1 (de) | Adsorbens fuer die affinitaetsspezifische trennung von makromolekularen stoffen, verfahren zu seiner herstellung und seine verwendung | |
EP1668126B1 (de) | Verfahren zur in vitro evolution von polypeptiden | |
EP1025253B1 (de) | Positiv-negativ-selektion bei der homologen rekombination | |
DE60129809T2 (de) | In vitro evolution von nukleinsäuren und kodierten polypeptiden | |
US20030027194A1 (en) | Modular assembly of nucleic acid-protein fusion multimers | |
DE69629808T2 (de) | Promotoren für Gen Expression | |
EP0453969B1 (de) | Verfahren zur Herstellung von Fremdproteinen in Streptomyceten | |
DE10116585A1 (de) | Peptidakzeptor/tRNA-Hybridmolekül und seine Verwendung zur Herstellung von Codon-spezifisch arretierten Translationskomplexen | |
WO2006103106A1 (de) | Ligation synthetischer zinkfinger-peptide zu seriellen bindeproteinen für die spezifische adressierung doppelsträngiger dna-bereiche (zinkfinger-sonden) | |
CA2012025A1 (en) | Dna for expression and secretion | |
WO1999036430A1 (de) | Oligoliganden mit bindungsvermögen | |
DE102007056818A1 (de) | Bakteriophagen und Beschichtungsmaterial für Oberflächen | |
DD263994A1 (de) | Verfahren zur herstellung von oligodesoxyribonucleotiden zur splenopentinexpression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8100 | Publication of the examined application without publication of unexamined application | ||
D1 | Grant (no unexamined application published) patent law 81 | ||
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: EVOTEC BIOSYSTEMS AG, 22525 HAMBURG, DE |
|
8327 | Change in the person/name/address of the patent owner |
Owner name: EVOTEC OAI AG, 22525 HAMBURG, DE |
|
8327 | Change in the person/name/address of the patent owner |
Owner name: DIREVO BIOTECH, 50829 KOELN, DE |
|
R082 | Change of representative |
Representative=s name: VON KREISLER SELTING WERNER, DE |
|
R081 | Change of applicant/patentee |
Owner name: EVOTEC AG, DE Free format text: FORMER OWNER: DIREVO BIOTECH, 50829 KOELN, DE Effective date: 20130123 |
|
R082 | Change of representative |
Representative=s name: VON KREISLER SELTING WERNER - PARTNERSCHAFT VO, DE Effective date: 20130123 Representative=s name: VON KREISLER SELTING WERNER, DE Effective date: 20130123 |
|
R071 | Expiry of right |